Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials
AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they had been co-developing, the newest blow within the lengthy quest to discover a breakthrough for the memory-robbing dysfunction.
The businesses mentioned the choice was taken after an impartial information monitoring committee concluded that trials related to lanabecestat, the experimental drug, wouldn’t obtain their authentic objectives. The businesses mentioned the remedy wasn’t working in addition to that they had hoped and ending the trials…
Supply hyperlink – https://www.wsj.com/articles/eli-lilly-astrazeneca-drop-two-late-stage-alzheimers-drug-trials-1528797681?mod=pls_whats_news_us_business_f